Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years

Schlaeger, Regina; Schindler, Christian; Grize, Leticia; Dellas, Sophie; Radüe, Ernst Wilhelm; Kappos, Ludwig; Fuhr, Peter

doi:10.1177/1352458514525867

Cited by 45 publications

(47 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 28 prospectively followed adult patients with MS, combined VEP and motor evoked potentials (MEP, central motor conduction time for abductor digiti minimi and anterior tibial muscles) predicated disability, as measured by the EDSS, after 20 years disease duration, accounting for age and therapy status (p 5 0.01). 38 In fact, VEP and MEP predicted 58% of the variability in EDSS at year 20, whereas the baseline EDSS or MRI features (number of T2 hyperintense or gadolinium-enhancing lesions) did not improve the prediction model. Similar studies have not been performed in pediatric MS.…”

Section: Outcome Measuresmentioning

confidence: 99%

Pediatric multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

Multiple sclerosis (MS) in children manifests with a relapsing-remitting MS (RRMS) disease course. Acute relapses consist of new neurologic deficits persisting greater than 24 hours, in the absence of intercurrent illness, and occur with a higher frequency early in the disease as compared to adult-onset RRMS. Most pediatric patients with MS recover well from these early relapses, and cumulative physical disability is rare in the first 10 years of disease. Brainstem attacks, poor recovery from a single attack, and a higher frequency of attacks portend a greater likelihood of future disability. Although prospective pediatric-onset MS cohorts have been established in recent years, there remains very limited prospective data detailing the longer-term clinical outcome of pediatric-onset MS into adulthood. Whether the advent of MS therapies, and the largely off-label access to such therapies in pediatric MS, has improved prognosis is unknown. MS onset during the key formative academic years, concurrent with active cognitive maturation, is an important determinant of long-term outcome, and is discussed in detail in another article in this supplement. Finally, increasing recognition of pediatric MS worldwide, recent launch of phase III trials for new agents in the pediatric MS population, and the clear imperative to more fully appreciate health-related quality of life in pediatric MS through adulthood highlight the need for standardized, validated, and robust outcome measures. Neurology ® 2016;87 (Suppl 2):S74-S81

show abstract

Section: Outcome Measuresmentioning

confidence: 99%

Pediatric multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…At baseline, the median age was 38 (IQR: 31-45) and disease duration 7 years (IQR: [2][3][4][5][6][7][8][9][10][11][12][13][14]. The majority of patients were in the relapsingremitting phase (RR = 90 %).…”

Section: Resultsmentioning

confidence: 99%

“…Prospective and retrospective studies have demonstrated the good accuracy of models including multimodal EP alone [5,6] or associated with other factors designed to monitor and predict the functional evolution [7][8][9].…”

Section: Introductionmentioning

confidence: 98%

Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?

et al. 2016

View full text Add to dashboard Cite

The clinical variability and complexity of multiple sclerosis (MS) challenges the individual clinical course prognostication. This study aimed to find out whether multimodal evoked potentials (EP) correlate with the motor components of multiple sclerosis functional composite (MSFCm) and predict clinically relevant motor functional deterioration. One hundred MS patients were assessed at baseline (T ) and about 7.5 years later (T), with visual, somatosensory and motor EP and rated on the Expanded Disability Status Scale (EDSS) and the MSFCm, including the 9 Hole Peg Test and the Timed 25 Foot Walk (T25FW). The Spearman correlation coefficient (r ) was used to evaluate the cross-sectional and longitudinal relationship between EP Z scores and clinical findings. The predictive value of baseline electrophysiological data for clinical worsening (EDSS, 9-HPT, T25FW, MSFCm) during follow-up was assessed by logistic regression analysis. Unlike longitudinal correlations, cross-sectional correlations between EP Z scores and clinical outcomes were all significant and ranged between 0.22 and 0.67 (p< 0.05). The global EP Z score was systematically predictive of EDSS and MSFCm worsening over time (all p < 0.05). EP latency was a better predictor than amplitude, although weaker than latency and amplitude aggregation in the global EP Z score. The study demonstrates that EP numerical scores can be used for motor function monitoring and outcome prediction in patients with MS.

show abstract

“…By assessing the functional integrity of neuronal pathways, evoked potentials have been shown to be especially sensitive for subclinical lesions in MS thereby allowing even the prediction of long-term disability (Schlaeger et al, 2014). Since the association between EPs and the BDNF status has not been investigated so far we implemented EPs at 12 months intervals in our study cohort.…”

Section: Discussionmentioning

confidence: 99%

Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial

Ehling

Pauli

Lackner

et al. 2015

Journal of Neuroimmunology

View full text Add to dashboard Cite

Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years

Abstract: These results further support a role for combined EP-measures as predictors of long-term disability in MS.

Cited by 45 publications

References 39 publications

Pediatric multiple sclerosis

Pediatric multiple sclerosis

Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?

Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial

Contact Info

Product

Resources

About